Clomiphene citrate (CC) is an oral therapy for secondary hypogonadism. This study examined its effect on serum testosterone, luteinizing hormone (LH), and beta-human chorionic gonadotropin (beta-HCG) in testicular cancer survivors who developed hypogonadism after chemotherapy.
Methods: Following IRB approval, researchers conducted a retrospective review of male patients who underwent radical orchiectomy and chemotherapy for testicular cancer from 2004 to 2022. Inclusion criteria included age over 18 and symptomatic hypogonadism (testosterone <300 ng/dL) treated with CC. Testosterone changes were analyzed using paired, two-tailed t-tests, while LH and beta-HCG levels were assessed using one-tailed, two-sample t-tests.
Results: Of 476 radical orchiectomies, 10 patients met inclusion criteria. CC therapy increased mean serum testosterone by 273 ng/dL (from 215 to 486 ng/dL) over a mean follow-up of 52.5 months. No side effects, disease recurrence, or false-positive elevations in beta-HCG were observed.
Conclusion: CC effectively raises testosterone in hypogonadal testicular cancer survivors post-chemotherapy without adverse effects or tumor marker interference. These findings support CC as a safe alternative to testosterone replacement therapy in patients desiring fertility preservation.
Introduction
Testicular cancer is the most common malignancy in males aged 15–39, with cure rates exceeding 95%. However, approximately 38% of survivors experience hypogonadism after radical orchiectomy and chemotherapy. Hypogonadism is defined by low testosterone (<300 ng/dL) and symptoms including fatigue, low libido, erectile dysfunction, and reduced muscle mass.
Standard treatment involves testosterone replacement therapy (TRT), but exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, impairing fertility. Clomiphene citrate (CC), a selective estrogen receptor modulator, stimulates endogenous LH and FSH production, boosting testosterone while preserving spermatogenesis. Despite being a low-cost oral therapy, CC remains underutilized in post-chemotherapy testicular cancer patients due to concerns about false-positive beta-HCG elevations and doubts about efficacy in primary hypogonadism.
This study aimed to determine whether CC could safely normalize testosterone levels in these patients without affecting beta-HCG tumor markers.
Materials & Methods
After IRB approval, researchers identified patients with testicular germ cell tumors who had undergone radical orchiectomy and chemotherapy between 2004 and 2021. Inclusion required age >18, symptomatic hypogonadism (testosterone <300 ng/dL, LH <10 IU/L), and CC therapy (25–50 mg daily). Patients treated with TRT, radiation, or CC for <30 days were excluded.
Primary outcomes measured serum testosterone. Secondary outcomes included LH and beta-HCG. Hormone levels were assessed using standard electro-chemiluminescent immunoassays. Statistical analyses used paired t-tests for testosterone and one-tailed t-tests for LH and beta-HCG, with significance set at p < 0.05.
Results
Out of 476 radical orchiectomy cases, 10 patients met inclusion criteria. Nine pursued CC therapy to preserve fertility, and one chose it over TRT. CC increased mean serum testosterone by 273 ng/dL (p < 0.001), with 80% of patients requiring 25 mg daily and 20% requiring 50 mg.
Mean follow-up was 53.6 months. No patients experienced side effects, disease recurrence, or false-positive beta-HCG elevations. All beta-HCG levels remained <1.0 IU/L. Only one comorbidity, contralateral testicular microlithiasis, was noted.
Discussion & Conclusion
This is the first study to evaluate CC in post-chemotherapy testicular cancer survivors with hypogonadism. CC effectively increased testosterone without adverse effects or tumor marker interference. These results support CC as a safe, fertility-preserving alternative to TRT. Further research with larger cohorts is needed to confirm these findings and define clinical guidelines for CC use in this population.
Related topic：
